Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current experience with high-dose carboplatin therapy.

J F Bishop1

  • 1Department of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.

Seminars in Oncology
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chinese Doctors and Medical Treatment.

Buffalo medical journal·2023
Same author

Intensified Induction and Post-Remission Therapy for Acute Myeloid Leukaemia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Phase II study of acivicin in patients with recurrent high grade astrocytoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2008
Same author

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography.

Journal of chromatography. B, Biomedical sciences and applications·2002
Same author

Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.

British journal of haematology·2001
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

High-dose carboplatin is a promising chemotherapy option, with myelosuppression as the main dose-limiting toxicity. Further research into escalated doses and combinations is warranted for various cancers.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Carboplatin is a platinum-based chemotherapy agent.
  • Its dose-limiting toxicity is primarily myelosuppression at 1,200 mg/m2 without marrow support.

Purpose of the Study:

  • To evaluate the tolerability and potential of escalated carboplatin doses.
  • To explore carboplatin combinations in various cancers.

Main Methods:

  • Dose escalation studies of carboplatin.
  • Investigational use of repeated 800 mg/m2 doses.
  • Assessment of maximum tolerated single-agent dose with autologous bone marrow rescue.

Main Results:

  • Maximum tolerated single-agent dose with bone marrow rescue is 1.8-2 g/m2.
  • Dose-limiting toxicities include hepatitis, renal dysfunction, and ototoxicity.

Related Experiment Videos

  • Combinations are being investigated for germ cell tumors, ovarian, breast, and small cell lung cancer.

    • Conclusions:

    • Carboplatin is suitable for dose escalation.
    • Further investigation of high-dose carboplatin, potentially guided by renal clearance, is warranted.
    • Combination therapies show promise for treating various malignancies.